Fundraising FoxGlobal Health Investment Fund — 2023 Investments
2 investments dated 2023 · listed companies and verified rows first · show all
Ophirex is a biotech company developing varespladib, an investigational oral capsule intended to treat snakebite envenomation by inactivating a key venom toxin found in most snake species.
BiotechDeep TechHealthtechCorte Madera, US
Jerry Harrison(Co-founder; Director)Matthew R. Lewin(Founder and Board Member)inJeremy Gowler(Chief Executive Officer & Board Director)inSara Carter(Executive)Timothy Platts-Mills(Executive)Dotson(Finance leader (Controller/Finance))
.jpg)
Co-investorsTullis Health Investors
Vedanta Biosciences is a clinical-stage biotech developing Live Biotherapeutic Products (LBP) based on defined consortia of bacteria to treat serious gastrointestinal diseases, with an initial focus on preventing recurrent Clostridium difficile infection.
BiotechHealthtechCambridge, US
Bernat Olle(Executive Officer, Director)inDaniel Couto(Executive Officer)inMark Mullikin(Executive Officer)inJeffrey Silber(Executive Officer)inChristopher Viehbacher(Director)
BoardJohn LaMattina(Director)in
Co-investorsAMR Action FundK2 HealthVenturesSalica InvestmentsSeventure PartnersBNP ParibasBNP Paribas Asset Management Europe+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.